Spautin-1通过抑制自噬可增强舒尼替尼诱导的肾癌细胞凋亡

目的:研究spautin-1(一种自噬抑制剂)是否能抑制舒尼替尼诱导的肾癌细胞的自噬以及对舒尼替尼诱导的肾癌细胞凋亡的影响。方法:以肾癌细胞系786-O细胞为模型,Western Blot检测spautin-1对舒尼替尼诱导786-O细胞自噬的影响;Cell Counting Kit-8(CCK-8)检测spautin-1和舒尼替尼对786-O细胞增殖的影响;应用流式细胞术,检测spautin-1对舒尼替尼诱导的786-O细胞凋亡的影响;Western Blot检测spautin-1的促凋亡作用与PI3K/AKT/GSK3β信号通路及抗凋亡蛋白Bcl-2和Mcl-1的关系。结果:与舒尼替尼单独处理组相比,spautin-1能通过降低Beclin-1的表达显著抑制舒尼替尼在786-O细胞中诱导的自噬;Spautin-1和舒尼替尼联合作用明显增强舒尼替尼对786-O细胞增殖的抑制作用;Spautin-1能进一步增强舒尼替尼诱导的786-O细胞的凋亡;Spautin-1和舒尼替尼联合处理786-O细胞时,可以显著降低p-AKTSer473和p-GSK3βSer9的蛋白表达水平,增强GSK3β的活性,进而下调Bcl-2、Mcl-1的表达。结论:Spautin-1能通过抑制AKT活性并活化GSK3β,进一步降低抗凋亡蛋白Bcl-2、Mcl-1的表达,增强舒尼替尼诱导的肾癌细胞凋亡。     

自噬与非小细胞肺癌对吉非替尼耐药关系的实验研究

目的:探讨细胞自噬与非小细胞肺癌对Gefitinib耐药的相关性,寻找逆转非小细胞肺癌对Gefitinib耐药的新靶点。方法:以体外培养的人非小细胞肺癌Gefitinib敏感细胞PC-9与Gefitinib耐药细胞PC-9/GR为研究对象,通过MTT法检测Gefitinib对PC-9及PC-9/GR细胞存活率的影响;Western blot检测Gefitinib对PC-9及PC-9/GR细胞中自噬相关蛋白LC3的表达的影响;流式细胞术检测自噬诱导剂雷帕霉素和Gefitinib对PC-9/GR细胞凋亡率的影响。结果:PC-9/GR细胞Gefitinib IC50为PC-9细胞的200倍以上,具有非常明显的耐药性。PC-9/GR细胞中LC3II的表达显著低于PC-9/GR细胞(P0.05)。Rapamycin联合Gefitinib作用于PC-9/GR细胞可以明显提高其细胞凋亡率(P0.05)。结论:细胞自噬减弱与非小细胞肺癌对Gefitinib耐药有关,诱导细胞自噬可能逆转非小细胞肺癌对Gefitinib耐药。     

呼吸道合胞病毒诱导细胞凋亡与自噬

呼吸道合胞病毒感染与细胞凋亡、自噬的关系错综复杂。研究发现呼吸道合胞病毒感染细胞后,既能产生促细胞凋亡作用,也能产生抗细胞凋亡作用,还能诱导细胞发生自噬。研究这些过程机理,能帮助我们更好地认识呼吸道合胞病毒感染发病机制,为预防和治疗呼吸道合胞病毒感染提供一些新的方向。     

细胞自噬在吉非替尼治疗非小细胞肺癌中的作用及其机制研究

目的:观察吉非替尼对非小细胞肺癌细胞自噬的影响,并探讨其机制。方法:将BalB/CA-nu品系裸小鼠分成两组,各组20只,均造肺癌模型,其中吉非替尼治疗组小鼠在肺癌组模型的基础上给予吉非替尼25mg/kg 14d,停药后剖杀。取组织切片,通过免疫荧光、RT-PCR以及Western blot的试验方法检测自噬相关基因Beclin1和MAPLC3的表达。结果:免疫荧光、RT-PCR以及Western blot的试验方法检测均发现肺癌组小鼠组织中Beclin1和MAPLC3表达较低,而在吉非替尼处理组中,Beclin1和MAPLC3的表达明显升高,差异有统计学意义。结论:吉非替尼可以通过增强细胞自噬从而发挥对非小细胞肺癌的抑制作用。     

高糖通过诱导自噬障碍促进心肌细胞H9c2凋亡

目的探讨自噬对高糖（HG）诱导的心肌细胞H9c2凋亡的影响。 方法MTT法检测H9c2细胞活力;hoechst33258染色法检测凋亡细胞;Western Blot检测H9c2细胞促凋亡蛋白Bax和自噬相关蛋白（Beclin-1和P62）的表达。各组的OD值和蛋白条带灰度值均采用析因设计的方差分析,各组间差异用单因素ANOVA分析。 结果HG能诱导H9c2细胞活力降低：12、24、48 mmol/L的HG细胞活力分别为Control组（100%）的[（79.5±2.23）%]（t = 3.143,P = 0.043）、[（54.6±3.08）%]（t = 12.425,P = 0.000）和[（37.2±2.59）%]（t = 13.761,P = 0.000）;与Control组（100%）比较,甘露醇等渗对照组的细胞活力值为[（101.0±1.27）%]（t = 0.012,P = 0.094）。HG诱导H9c2细胞hoechst33258阳性细胞增加,且能诱导促凋亡蛋白Bax表达增加：与Control组比较,12、24、48 mmol/L的HG处理组凋亡蛋白Bax/β-actin灰度值分别为（1.29±0.25,t = 2.32,P = 0.045）、（1.42±0.23,t = 10.247,P = 0.000）和（1.81±0.29,t = 16.324,P = 0.000）。HG诱导自噬障碍：与Control组比较,自噬相关蛋白Beclin-1/β-actin灰度值分别为（0.82±0.16,t = 4.243,P = 0.032）、（0.78±0.19,t = 11.341,P = 0.000）和（0.62±0.11,t = 13.455,P = 0.000）,P62蛋白/β-actin蛋白灰度值分别为（1.29±0.25,t = 4.442,P = 0.014）、（1.42±0.23,t = 13.341,P = 0.000）和（1.81±0.29,t = 15.851,P = 0.000）。自噬诱导剂雷帕霉素可逆转HG诱导的hoechst33258阳性细胞增加,且逆转HG诱导的Bax表达升高：与control组比较,HG组、HG和雷帕霉素共处理组、雷帕霉素组的Bax/β-actin灰度值分别为（1.51±0.31,t = 14.342,P = 0.000）、（1.42±0.23,t = 9.621,P = 0.004）和（1.81±0.12,t = 0.172,P = 0.124）。 结论HG可促进心肌细胞H9c2凋亡,且能诱导自噬障碍,自噬诱导剂的运用逆转了HG对H9c2细胞的凋亡作用,表明自噬障碍是HG诱导H9c2细胞凋亡的重要机制。     

索拉非尼与舒尼替尼单药治疗晚期肝细胞癌的效果分析

目的:对比索拉非尼(Sorafenib)和舒尼替尼(Sunitinib)单药治疗晚期肝细胞癌的疗效及安全性。方法:对我院2004年1月-2010年10月收治的44例晚期肝细胞肝癌患者的临床资料进行回顾分析。根据不同给药方式,将患者分为两组。其中,索拉非尼组32例患者采取口服索拉非尼进行治疗,而舒尼替尼组12例患者给予口服舒尼替尼治疗。观察并比较两组患者的治疗效果及药物不良反应情况。结果:索拉非尼组总生存时间为6.3月,1年生存率为16%,肿瘤进展时间为3个月,疾病控制率为71%;舒尼替尼组总生存时间为4.7月,1年生存率为8%,肿瘤进展时间为3个月,疾病控制率为64%。两组临床效果差异无统计学意义(P=0.2415,0.5706,0.7132)。索拉非尼组患者手足皮肤反应、中性粒细胞减少及肝损伤等主要毒副反应的发生率均低于舒尼替尼组,差异具有统计学意义(P0.05)。结论:索拉非尼治疗晚期肝细胞肝癌的临床效果与舒尼替尼具有很好的一致性,药物不良反应相对较轻,患者依从性较好,值得临床推广应用。     

磷酸腺苷激活的蛋白激酶(AMPK)参与了曲格列酮诱导的HeLa细胞自噬和凋亡

【目的】明确磷酸腺苷激活的蛋白激酶(AMPK)在细胞自噬和凋亡中的作用。【方法】利用电镜、荧光显微镜、蛋白免疫杂交、siRNA干扰、流式细胞计数、MTS细胞活性检测等对曲格列酮(troglitazone,TZ)处理的HeLa细胞自噬和凋亡情况进行了检测。【结果】不同检测方法均表明TZ增加了HeLa细胞的自噬,这种自噬的发生伴随着AMPK的磷酸化的降低;抑制AMPK增加基础细胞自噬,而阻断了TZ引起的自噬标记物LC3-II的增加,同时也减少了TZ引起的凋亡分子PARP的切割;用自噬抑制剂3-MA和干扰细胞自噬基因,不仅PARP的切割明显地受到抑制,而且也部分阻断了TZ引起的细胞活性丧失。【结论】AMPK直接参与了TZ引起的HeLa细胞自噬过程,这种自噬发生促进了其诱导的细胞凋亡。     

雷公藤甲素诱导HeLa细胞p53依赖的自噬和凋亡

自噬与凋亡被认为是细胞程序性死亡的两种重要途径,二者的交互联系对阐明药物的抗肿瘤机理有重要价值.众多的研究表明,雷公藤甲素对多种肿瘤细胞都具有显著的抑制作用.细胞凋亡与自噬可被相同的因素所诱导,p53蛋白可以同时对二者起调控作用,在自噬与凋亡的交互作用(crosstalk)中扮演着重要角色.本文以He La细胞为模型,研究雷公藤甲素诱导He La细胞发生自噬和凋亡的机制,并通过抑制p53依赖的转录,研究雷公藤甲素诱导He La细胞p53依赖的自噬和凋亡交互联系.     

自噬及其在癌细胞中作用机制的研究

自噬是广泛存在于真核细胞中的生命现象,是以细胞质空泡化为特征的溶酶体依赖性的降解途径。自噬从酵母至哺乳动物细胞均很保守,它在耐受饥饿和缺血、清除衰老细胞器、清除细菌和异物、维持细胞活性和延长寿命等方面起着非常重要的作用。该文主要对自噬体的发生过程、分子机制及在癌细胞中的调控作用等方面进行简要概述。     

自噬在应力诱导成肌细胞凋亡中的作用初探

目的:探讨自噬在周期性张应力介导的成肌细胞凋亡中的作用,以明确应力诱导内质网应激引起自噬与凋亡之间的关系。方法:在成功构建L6大鼠体外培养--力学刺激模型的基础上,采用Western Blot法分析周期性张应力对自噬相关蛋白LC3蛋白表达的影响,并通过Annexin V-FITC/PI流式细胞术检测细胞凋亡情况。加力组分别给予1,6,12,24 h的力学刺激(拉伸变形率为15%,频率为10循环/min),3-MA组和Rapamycin组在加力2 h前分别加入自噬抑制剂3-甲基腺嘌呤和自噬激活剂雷帕霉素并且加力24 h,0 h组与实验组在同时种板但是不给予力刺激。采用SPSS17.0统计软件对以上数据进行统计分析。结果:成肌细胞中的LC3II/LC3I值随加力时间延长呈上升趋势,24 h达最高(P0.05);抑制组的细胞凋亡率(18.75±1.06%)相对于0 h组(0.726±0.13%)和加力24 h组(14.84±1.14%)的明显升高(P0.05);Rapamycin组相对于加力24 h组的细胞凋亡率明显下降(8.88±1.08%vs 14.84±1.14%),但是细胞凋亡率仍然高于0 h组的(8.88±1.08%vs 0.726±0.13%)。结论:在一定时间范围内,周期性张应力可诱导成肌细胞发生自噬,并且自噬活性与作用时间成正比;自噬可以降低应力介导的成肌细胞凋亡的活性。     

Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP‐BEZ235 in renal cell carcinoma cells

The PI3K/AKT/mTOR pathway plays a key role in the development of the hypervascular tumor renal cell carcinoma (RCC). NVP‐BEZ235 (NVP), a novel dual PI3K/mTOR inhibitor, showed great antitumor benefit and provided a treatment strategy in RCC. In this study, we test the effect of NVP on survival rate, apoptosis and autophagy in the RCC cell line, 786‐0. We also explore the hypothesis that NVP, in combination with autophagy inhibitors, leads to apoptosis enhancement in 786‐0 cells. The results showed that the PI3K/AKT/mTOR pathway proteins p‐AKT and p‐P70S6K were highly expressed in RCC tissue. We also showed that NVP inhibited cell growth and induced apoptosis and autophagy in RCC cells. The combination treatment of NVP with autophagy inhibitors enhanced the effect of NVP on suppressing 786‐0 growth and induction of apoptosis. This study proposes a novel treatment paradigm where combining PI3K/AKT/mTOR pathway inhibitors and autophagy inhibitors lead to enhanced RCC cell apoptosis. Copyright © 2012 John Wiley & Sons, Ltd.     

细胞自噬与凋亡的交互作用

细胞自唾又称Ⅱ型程序性细胞死亡,参与了多种疾病的发生和发展。自唆与凋亡之间存在着复杂的交互调控——二者能被多种应激刺激共同激活、共享多个调节分子,甚至互相协调转化等。全面深入研究自噬与凋亡之间的交互作用机制,将为肿瘤等疾病的认知及治疗带来突破性进展。     

Suppressing ROS-TFE3-dependent autophagy enhances ivermectin-induced apoptosis in human melanoma cells

Melanoma is an aggressive skin malignancy with a high mortality rate; however, successful treatment remains a clinical challenge. Ivermectin, a broad-spectrum antiparasitic drug, has recently been characterized as a potential anticancer agent due to its observed antitumor effects. However, the molecular mechanisms of ivermectin remain poorly understood. In the current study, we tested the involvement of autophagy in the ivermectin mechanism of action in human melanoma cells. We exposed SK-MEL-28 cells to different concentrations of ivermectin (2.5, 5, and 10 μM) for 24 hours. Here, ivermectin-induced apoptosis, as evidenced by the upregulation of cleaved poly (ADP-ribose) polymerase, BAX expression, and caspase-3 activity and downregulation of BCL-2 expression. In line with the apoptosis response, ivermectin triggered autophagy. Pharmacological or genetic inhibition of autophagy further sensitized SK-MEL-28 cells to ivermectin-induced apoptosis. Mechanistically, ivermectin-induced TFE3^(Ser321) dephosphorylation, activated TFE3 nuclear translocation and increased TFE3 reporter activity, which contributed to lysosomal biogenesis and the expression of autophagy-related genes, and subsequently, initiated autophagy in SK-MEL-28 cells. Moreover, N-acetyl-cysteine, an reactive oxygen species (ROS) scavenger, abrogated the effects of ivermectin on TFE3-dependent autophagy. Taken together, we demonstrated that ivermectin increases TFE3-dependent autophagy through ROS signaling pathways in human melanoma cells and that inhibiting autophagy enhances ivermectin-induced apoptosis in human melanoma cells.     

Depletion of NBR1 in urothelial carcinoma cells enhances rapamycin-induced apoptosis through impaired autophagy and mitochondrial dysfunction

Rapamycin is well-recognized in the clinical therapeutic intervention for patients with cancer by specifically targeting mammalian target of rapamycin (mTOR) kinase. Rapamycin regulates general autophagy to clear damaged cells. Previously, we identified increased expression of messenger RNA levels of NBR1 (the neighbor of BRCA1 gene; autophagy cargo receptor) in human urothelial cancer (URCa) cells, which were not exhibited in response to rapamycin treatment for cell growth inhibition. Autophagy plays an important role in cellular physiology and offers protection against chemotherapeutic agents as an adaptive response required for maintaining cellular energy. Here, we hypothesized that loss of NBR1 sensitizes human URCa cells to growth inhibition induced by rapamycin treatment, leading to interruption of protective autophagic activation. Also, the potential role of mitochondria in regulating autophagy was tested to clarify the mechanism by which rapamycin induces apoptosis in NBR1-knockdown URCa cells. NBR1-knockdown URCa cells exhibited enhanced sensitivity to rapamycin associated with the suppression of autophagosomal elongation and mitochondrial defects. Loss of NBR1 expression altered the cellular responses to rapamycin treatment, resulting in impaired ATP homeostasis and an increase in reactive oxygen species (ROS). Although rapamycin treatment-induced autophagy by adenosine monophosphate-activated protein kinase (AMPK) phosphorylation in NBR1-knockdown cells, it did not process the conjugated form of LC3B-II after activation by unc-51 like autophagy-activating kinase 1 (ULK1). NBR1-knockdown URCa cells exhibited rather profound mitochondrial dysfunctions in response to rapamycin treatment as evidenced by Δψm collapse, ATP depletion, ROS accumulation, and apoptosis activation. Therefore, our findings provide a rationale for rapamycin treatment of NBR1-knockdown human urothelial cancer through the regulation of autophagy and mitochondrial dysfunction by regulating the AMPK/mTOR signaling pathway, indicating that NBR1 can be a potential therapeutic target of human urothelial cancer.     

AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells

10-hydroxycamptothecin (HCPT), a natural plant extract, exerts anticancer capacity. HCPT has been reported to induce apoptosis and autophagy in human cancer cells. The interaction between autophagy and apoptosis induced by HCPT and the molecular mechanism in bladder cancer cells were investigated in this study. Our results confirmed that HCPT suppressed cell viability and migration and caused cell-cycle arrest in T24 and 5637. Then, we used Z-VAD(OMe)-FMK to clarify that apoptosis induced by HCPT was mediated by caspase. Moreover, HCPT boosted autophagy through activating the AMPK/mTOR/ULK1 pathway. Blocking autophagy by 3-methyladenine, the adenosine monophosphate-activated protein kinase (AMPK) inhibitor dorsomorphin and siATG7 reversed HCPT-induced cytotoxicity. Conversely, rapamycin and the AMPK activator AICAR enhanced growth inhibition and cell apoptosis, suggesting that autophagy played a proapoptosis role. Taken together, our findings showed that HCPT-induced autophagy mediated by the AMPK pathway in T24 and 5637 cell lines, which reinforced the apoptosis, indicating that HCPT together with autophagy activator would be a novel strategy for clinical treatment in bladder cancer.